StreetAlpha.app
Home › Stocks › IRON

Disc Medicine, Inc. (IRON)

Healthcare
$76.57
▼ −0.03%
LAST CLOSE · NOV 17

Disc Medicine develops experimental drugs for serious blood disorders, based in Watertown, Massachusetts. It last closed at $76.57 on Nov 17, down 0.03% on the day. The average 12-month price target from 8 analysts is $122.50 (+60.0% from the last close), with a high of $170.00 and a low of $92.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 5 whale options trades in IRON, 40% of them bullish and 60% bearish. In the past 30 days there were 3 dark pool prints totaling $8.6M, the largest $6.1M.

AI Auto Pilots
Is IRON in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$243.1M
EPS (diluted)
−$6.34
Free cash flow
−$190.0M
Valuation
Market cap
$3.5B
45.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$90.0M
At Sep 30
Debt
$59.7M
At Sep 30
Shareholder equity
$604.3M
Shares outstanding
45.5M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$36.0M−$36.0MFY2021FY2022: −$46.8M−$46.8MFY2022FY2023: −$76.4M−$76.4MFY2023FY2024: −$109.4M−$109.4MFY2024FY2025: −$212.2M−$212.2MFY2025

From IRON's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
8firms
8 Buy0 Hold0 Sell
Each firm's latest rating on IRON in the past 90 days
Average 12-month target
$122.50
▲ 60.0% upside

Based on 8 analysts who set a price target on IRON in the past 90 days. The average target is $122.50, with a high of $170.00 and a low of $92.00, compared with the last close of $76.57.

Low $92.00Avg $122.50High $170.00
Blue marker: last close $76.57
Highest target$170.00
Average target$122.50
Lowest target$92.00
Latest rating changes
GuggenheimInitiated
Nov 9Buy$132
HC Wainwright & Co.Target raised
Nov 6Buy$120 → $127
Morgan StanleyTarget raised
Oct 20Buy$85 → $92
Truist SecuritiesMaintained
Oct 20Buy$115
Wells FargoTarget raised
Oct 20Buy$86 → $124
DateFirmActionRatingPrice target
Nov 9GuggenheimInitiatedBuy$132
Nov 6HC Wainwright & Co.Target raisedBuy$120 → $127
Oct 20Morgan StanleyTarget raisedBuy$85 → $92
Oct 20Truist SecuritiesMaintainedBuy$115
Oct 20Wells FargoTarget raisedBuy$86 → $124
Loading…

Technical Analysis

IRON · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 7% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the swing low (Sep 1) at $75.88, and the nearest resistance the Pivot at $76.60.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 5.2%/day
Key levels
$99.5052 week high+29.9%
$79.9920 day average+4.5%
$77.86Pivot R1+1.7%
$77.48Swing high (Jul 20)+1.2%
$76.60Pivot+0.0%
$76.57Last close
$75.88Swing low (Sep 1)−0.9%
$75.31Pivot S1−1.6%
$74.66100 day average−2.5%
$71.5450 day average−6.6%
$70.92200 day average−7.4%
$40.0052 week low−47.8%
Indicators
RSI (14)49.09Middle of its rangeNeutral
MACD2.43Below its signal lineBearish
Stochastic14.5Near the bottom of its rangeOversold
ADX (14)32.5Trending up
Williams %R-89.9Oversold below −80, overbought above −20Oversold
CCI (20)-96.1Oversold below −100, overbought above 100Neutral
Rate of change−5.7%Change over 10 sessionsBearish
ATR (14)$3.98Typical daily range, 5.2% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for IRON

What happened before

See how IRON did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish2 bullish and 3 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow IRON usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IRON has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
5
Bullish
2
40%
Bearish
3
60%
Date span
Sep 14 – Oct 13
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$8.6M
Largest print
$6.1M
Loading…

IRON Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲135 buying vs 83 selling
  • ▲Held by funds +1.0 pts
  • ▲Funds holding +19
  • ▼Superinvestors: 0 added, 2 cut
  • ▼Put/call 0.18 to 1.17
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding237218+8.7%
In funds' top 10770.0%
Held by funds95.8%94.8%+1.0 pts
New / increased43 / 9236 / 75+21.6%
Reduced / sold out59 / 2462 / 22−1.2%
Put/call ratio1.170.18+551.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IRON institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IRON is in one of them and how their past IRON trades turned out.

IRON in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IRON in an article yet. Here's the latest on the wider market.

About Disc Medicine

Disc Medicine is a drug developer based in Watertown, Massachusetts, that focuses on treatments for serious blood disorders. Its work centers on the heme and iron pathways that help form red blood cells and carry oxygen. The company is developing bitopertin for porphyrias, DISC-0974 for anemia linked to myelofibrosis and inflammatory bowel disease, and DISC-3405 for polycythemia vera and sickle cell disease. Its product candidates are still in clinical development and are aimed at patients with blood diseases.

Headquarters
Watertown, MA